[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.

MLA

Booth, Laurence, et al. “[Pemetrexed + Sorafenib] Lethality Is Increased by Inhibition of ERBB1/2/3-PI3K-NFκB Compensatory Survival Signaling.” Oncotarget, vol. 7, no. 17, Apr. 2016, pp. 23608–32. EBSCOhost, https://doi.org/10.18632/oncotarget.8281.

APA

Booth, L., Roberts, J. L., Tavallai, M., Chuckalovcak, J., Stringer, D. K., Koromilas, A. E., Boone, D. L., McGuire, W. P., Poklepovic, A., & Dent, P. (2016). [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget, 7(17), 23608–23632. https://doi.org/10.18632/oncotarget.8281

Chicago

Booth, Laurence, Jane L Roberts, Mehrad Tavallai, John Chuckalovcak, Daniel K Stringer, Antonis E Koromilas, David L Boone, William P McGuire, Andrew Poklepovic, and Paul Dent. 2016. “[Pemetrexed + Sorafenib] Lethality Is Increased by Inhibition of ERBB1/2/3-PI3K-NFκB Compensatory Survival Signaling.” Oncotarget 7 (17): 23608–32. doi:10.18632/oncotarget.8281.